AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira sales drop.
There’s a lesson here for long-term leaders: When the time comes, let go. James Gorman at Morgan Stanley has definitely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback